Edition:
United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

108.51USD
14 Dec 2017
Change (% chg)

$0.31 (+0.29%)
Prev Close
$108.20
Open
$108.15
Day's High
$109.52
Day's Low
$107.95
Volume
2,674,384
Avg. Vol
6,219,831
52-wk High
$147.17
52-wk Low
$94.55

Chart for

About

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology... (more)

Overall

Beta: 1.77
Market Cap(Mil.): $85,219.19
Shares Outstanding(Mil.): 787.32
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.50 16.04
EPS (TTM): -- -- --
ROI: -- 15.11 35.70
ROE: -- 16.59 15.40

US STOCKS-Wall St ends higher with help from tech, energy

* Cryptocurrency related stocks bounce after bitcoin futures debut

Dec 11 2017

CORRECTED-US STOCKS-Wall St rises with help from technology, energy sectors

* Cryptocurrency related stocks bounce after bitcoin futures debut

Dec 11 2017

BRIEF-Celgene Reports Long-Term Efficacy Data From Phase III Geparsepto Study

* LONG-TERM EFFICACY DATA FROM THE PHASE III GEPARSEPTO STUDY IN HIGH RISK EARLY BREAST CANCER PATIENTS TREATED WITH ABRAXANE VS. SOLVENT-BASED PACLITAXEL TO BE REPORTED

Dec 07 2017

BRIEF-Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA

* Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA and prime eligibility from EMA for relapsed and refractory multiple myeloma

Nov 16 2017

U.S. opposes 'windfall' award to Celgene whistleblower

The U.S. Justice Department is opposing a former Celgene Corp sales manager's request for a nearly $77.8 million share of a recent $280 million settlement with the drugmaker, saying the sum would amount to an "inappropriate windfall."

Nov 15 2017

Celgene whistleblower seeks dismissal of law firm's lawsuit

A former Celgene Corp sales manager has urged a federal judge to dismiss a lawsuit by law firm Grant & Eisenhofer, which is seeking a cut of a $280 million settlement of a whistleblower lawsuit in which it previously represented her.

Nov 14 2017

BRIEF-Temasek Holdings (Private) Ltd ups share stake in Mastercard, Visa and Monsanto

* Temasek Holdings (Private) Ltd ups share stake in Mastercard to 923,068 class a shares from 267,006 class a shares

Nov 14 2017

BRIEF-Celgene prices $3 billion of senior unsecured notes

* Celgene Corp - ‍announced pricing of three series of senior unsecured notes for aggregate principal amount of $3,000 million​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Nov 01 2017

BRIEF-Celgene announces offering of senior unsecured notes

* Celgene-To use proceeds for repayment of $1 billion outstanding 2.125% senior notes & $400 million outstanding 2.300% senior notes, each maturing Aug 2018​ Source text for Eikon: Further company coverage:

Oct 31 2017

BRIEF-Lannett and Celgene enter into settlement and license agreement related to Thalomid

* Lannett and Celgene enter into settlement and license agreement related to Thalomid

Oct 30 2017

Competitors

  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥6,221 -53.00
Eisai Co., Ltd (4523.T) ¥6,895 +53.00
Johnson & Johnson (JNJ.N) $142.08 +0.43
Novartis AG (NOVN.S) CHF83.85 --
Pfizer Inc. (PFE.N) $36.46 -0.18
Roche Holding Ltd. (ROG.S) CHF241.70 0.00
Roche Holding Ltd. (RO.S) CHF242.50 -0.70
Merck & Co., Inc. (MRK.N) $56.01 -0.90
Sanofi SA (SASY.PA) €73.77 -0.89
AstraZeneca plc (AZN.L) 4,881.00 -3.50

Earnings vs. Estimates